Session: Psychedelic Therapy for United States Military Veterans with a History of Combat and Deployment Trauma (Society for Social Work and Research 27th Annual Conference - Social Work Science and Complex Problems: Battling Inequities + Building Solutions)

All in-person and virtual presentations are in Mountain Standard Time Zone (MST).

SSWR 2023 Poster Gallery: as a registered in-person and virtual attendee, you have access to the virtual Poster Gallery which includes only the posters that elected to present virtually. The rest of the posters are presented in-person in the Poster/Exhibit Hall located in Phoenix A/B, 3rd floor. The access to the Poster Gallery will be available via the virtual conference platform the week of January 9. You will receive an email with instructions how to access the virtual conference platform.

91 Psychedelic Therapy for United States Military Veterans with a History of Combat and Deployment Trauma

Friday, January 13, 2023: 9:45 AM-11:15 AM
Desert Sky, 3rd Level (Sheraton Phoenix Downtown)
Cluster: Military Service Members, Veterans and Their Families
Symposium Organizer:
Alan Davis, PhD, The Ohio State University
There is a mental health crisis and an alarming increase in the incidence of suicides in Veterans, highlighting limited effective treatments for this population. Currently available pharmacological and psychotherapeutic treatments in the US demonstrate limited efficacy in addressing the spectrum of psychiatric symptoms in Veterans. Therefore, it is essential that novel and potentially curative treatment approaches are developed that can address the underlying etiology and spectrum of symptoms in the Veteran population. Psychedelic drug-assisted therapies demonstrate potential as transdiagnostic treatment approaches but are not FDA approved for use. Nevertheless, Veterans are seeking out such treatments in international locations where these treatments are legal. This symposium will provide the background and context for understanding why and where Veterans are seeking out psychedelic therapies outside the US, followed by data from retrospective and prospective studies that describe the preliminary short- and long-term outcomes of this treatment for mental health and substance misuse problems. Psychological mechanisms of the treatment will also be explored and discussed. Collectively, these findings suggest that psychedelic therapies may be promising transdiagnostic tools for treating the spectrum of neuropsychiatric symptoms in Veterans, but more research is needed in controlled laboratory settings in the US.
* noted as presenting author
Symposium Background and Overview
Alan Davis, PhD, The Ohio State University
Prospective Data from a Clinical Psychedelic Therapy Program in Mexico
Yitong Xin, MSW, MBA, The Ohio State University
See more of: Symposia